Sponsored by
A recent publication in Springer Nature reports preclinical results for an experimental gene therapy developed by the Scottish company Trogenix for glioblastoma (GBM). The therapy uses engineered DNA elements called Synthetic Super-Enhancers (SSEs), delivered via adeno-associated virus (AAV) vectors. The SSEs are designed to activate specifically in GBM stem-like cells by exploiting SOX2-driven transcriptional programs. Once activated, they deliver two payloads: HSV-TK for targeted tumor cell killing via a prodrug mechanism, and IL-12 to stimulate an anti-tumor immune response.
The approach was first validated in patient-derived GBM stem cell cultures, where SSE activity was seen in tumor cells but not in non-tumor neural cells. It was then tested in orthotopic, immunocompetent mouse models of GBM. In these models, a single dose led to rapid tumor regression within 1-2 weeks, with complete tumor clearance in 83% of treated animals. No tumor recurrence or significant toxicity was observed over 11 months, and re-challenged mice did not develop new tumors, suggesting a durable immune response.
A first-in-human Phase I/II GBM trial is planned for 2026.